Sampol, Júlia
Miravitlles, Marc
Sáez, María
Pallero, Mercedes
Sampol, Gabriel
Ferrer, Jaume
Funding for this research was provided by:
Menarini
Article History
Received: 15 June 2023
Accepted: 23 October 2023
First Online: 31 October 2023
Competing interests
: JF has received fees from AstraZeneca, Novartis, Boehringer Ingelheim, Chiesi and GlaxoSmihtKline, and a research grant from Air Liquide Foundation. MM has received speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Menarini, Kamada, Takeda, Zambon, CSL Behring, Specialty Therapeutics, Janssen, Grifols and Novartis, consulting fees from AstraZeneca, Atriva Therapeutics, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, CSL Behring, Inhibrx, Ferrer, Menarini, Mereo Biopharma, Spin Therapeutics, Specialty Therapeutics, ONO Pharma, Palobiofarma SL, Takeda, Novartis, Novo Nordisk, Sanofi, Zambon and Grifols and research grants from Grifols. JS, MS, MP and GS declare to have no conflict of interest. The funders had no role in the design of the study, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.